However, though there are upfront CGM device costs, a clinical trial by Wan et al. showed that CGM is cost-effective at the willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) for persons with type 1 diabetes mellitus compared to multiple insulin injections, which still lead inadequate glycemic control, while CGM improved glucose control [5]. The gene discussed is INS; the disease is type 1 diabetes mellitus.